 |
answer text |
<p>We have not seen any evidence that suggests there has been any changes to the volume
of medicine shortages or price changes as a result of the United Kingdom leaving the
European Union. Our number one priority is to ensure the continued supply of medicines
which is why we are working closely with industry and partners in the health system
to manage the impact of EU exit.</p><p> </p><p>The Department has well established
processes to manage and mitigate the small number of business as usual supply problems
that may arise at any one time due to manufacturing or distribution issues and this
has always been the case. We work closely with the Medicines and Healthcare products
Regulatory Agency (MHRA), NHS England and the pharmaceutical industry to prevent medicine
shortages, minimise the risks to patients and take appropriate action when shortages
do occur.</p>
|
 |
